|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun C, Gao W, Liu J, Cheng H and Hao J:
FGL1 regulates acquired resistance to Gefitinib by inhibiting
apoptosis in non-small cell lung cancer. Respir Res. 21:2102020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leonetti A, Sharma S, Minari R, Perego P,
Giovannetti E and Tiseo M: Resistance mechanisms to osimertinib in
EGFR-mutated non-small cell lung cancer. Br J Cancer. 121:725–737.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andrews Wright NM and Goss GD:
Third-generation epidermal growth factor receptor tyrosine kinase
inhibitors for the treatment of non-small cell lung cancer. Transl
Lung Cancer Res. 8 (Suppl 3):S247–S264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simeone JC, Nordstrom BL, Patel K and
Klein AB: Treatment patterns and overall survival in metastatic
non-small-cell lung cancer in a real-world, US setting. Future
Oncol. 15:3491–3502. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tran PN and Klempner SJ: Profile of
rociletinib and its potential in the treatment of non-small-cell
lung cancer. Lung Cancer (Auckl). 7:91–97. 2016.PubMed/NCBI
|
|
12
|
He J, Huang Z, Han L, Gong Y and Xie C:
Mechanisms and management of 3rd-generation EGFR-TKI resistance in
advanced non-small cell lung cancer (Review). Int J Oncol.
59:902021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan CS, Kumarakulasinghe NB, Huang YQ, Ang
YLE, Choo JR, Goh BC and Soo RA: Third generation EGFR TKIs:
Current data and future directions. Mol Cancer. 17:292018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Remon J, Steuer CE, Ramalingam SS and
Felip E: Osimertinib and other third-generation EGFR TKI in
EGFR-mutant NSCLC patients. Ann Oncol. 29 (Suppl_1):i20–i27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cooper AJ, Sequist LV and Lin JJ:
Third-generation EGFR and ALK inhibitors: Mechanisms of resistance
and management. Nat Rev Clin Oncol. 19:499–514. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F
and Ou SI: Beyond osimertinib: The development of third-generation
EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac
Oncol. 16:740–763. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang JC, Reckamp KL, Kim YC, Novello S,
Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, et al:
Efficacy and safety of rociletinib versus chemotherapy in patients
with EGFR-Mutated NSCLC: The results of TIGER-3, a phase 3
randomized study. JTO Clin Res Rep. 2:1001142020.PubMed/NCBI
|
|
18
|
Kim ES: Olmutinib: First global approval.
Drugs. 76:1153–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
H L, H X and H Y, . Research on the
third-generation epidermal growth factor receptor tyrosine kinase
inhibitor drugs and their patents. Chin J N Drugs. 31:1553–1559.
2022.
|
|
20
|
Kelly RJ, Shepherd FA, Krivoshik A, Jie F
and Horn L: A phase III, randomized, open-label study of ASP8273
versus erlotinib or gefitinib in patients with advanced stage
IIIB/IV non-small-cell lung cancer. Ann Oncol. 30:1127–1133. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dhillon S: Lazertinib: First approval.
Drugs. 81:1107–1113. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deeks ED: Furmonertinib: First approval.
Drugs. 81:1775–1780. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koch AL, Vellanki PJ, Drezner N, Li X,
Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Zirkelbach JF, et
al: FDA approval summary: Osimertinib for adjuvant treatment of
surgically resected non-small cell lung cancer, a collaborative
project orbis review. Clin Cancer Res. 27:6638–6643. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prenzel N, Fischer OM, Streit S, Hart S
and Ullrich A: The epidermal growth factor receptor family as a
central element for cellular signal transduction and
diversification. Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levantini E, Maroni G, Del Re M and Tenen
DG: EGFR signaling pathway as therapeutic target in human cancers.
Semin Cancer Biol. 85:253–275. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ward RA, Anderton MJ, Ashton S, Bethel PA,
Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA,
et al: Structure- and reactivity-based development of covalent
inhibitors of the activating and gatekeeper mutant forms of the
epidermal growth factor receptor (EGFR). J Med Chem. 56:7025–7048.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL,
Bian J, Xia YZ and Kong LY: EGFR mutation mediates resistance to
EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms
to clinical research. Pharmacol Res. 167:1055832021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wee P and Wang Z: Epidermal growth factor
receptor cell proliferation signaling pathways. Cancers (Basel).
9:522017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang L and Fu L: Mechanisms of resistance
to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5:390–401.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Q, Yu S, Zhao W, Qin S, Chu Q and Wu
K: EGFR-TKIs resistance via EGFR-independent signaling pathways.
Mol Cancer. 17:532018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soejima K, Yasuda H and Hirano T:
Osimertinib for EGFR T790M mutation-positive non-small cell lung
cancer. Expert Rev Clin Pharmacol. 10:31–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sabbah DA, Hajjo R and Sweidan K: Review
on epidermal growth factor receptor (EGFR) structure, signaling
pathways, interactions, and recent updates of EGFR inhibitors. Curr
Top Med Chem. 20:815–834. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu L, Ke L, Zhang Z, Yu J and Meng X:
Development of EGFR TKIs and options to manage resistance of
Third-generation EGFR TKI osimertinib: Conventional ways and immune
checkpoint inhibitors. Front Oncol. 10:6027622020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lamb YN: Osimertinib: A review in
previously untreated, EGFR Mutation-positive, advanced NSCLC.
Target Oncol. 16:687–695. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh M and Jadhav HR: Targeting non-small
cell lung cancer with small-molecule EGFR tyrosine kinase
inhibitors. Drug Discov Today. 23:745–753. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Patel H, Pawara R, Ansari A and Surana S:
Recent updates on Third generation EGFR inhibitors and emergence of
Fourth generation EGFR inhibitors to combat C797S resistance. Eur J
Med Chem. 142:32–47. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou C, Wang M, Cheng Y, Li H, Wang J and
Wu YL: AURA17 study of osimertinib in Asia-Pacific patients (pts)
with EGFR T790M-positive advanced non-small cell lung cancer
(NSCLC): Updated phase II results including overall survival (OS).
Ann Oncol. 29:IX1572018. View Article : Google Scholar
|
|
41
|
Goss G, Tsai CM, Shepherd FA, Bazhenova L,
Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, et al:
Osimertinib for pretreated EGFR Thr790Met-positive advanced
non-small-cell lung cancer (AURA2): A multicentre, open-label,
single-arm, phase 2 study. Lancet Oncol. 17:1643–1652. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Papadimitrakopoulou VA, Mok TS, Han JY,
Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J,
He Y, et al: Osimertinib versus platinum-pemetrexed for patients
with EGFR T790M advanced NSCLC and progression on a prior
EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Ann Oncol. 31:1536–1544. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng Y, He Y, Li W, Zhang HL, Zhou Q,
Wang B, Liu C, Walding A, Saggese M, Huang X, et al: Osimertinib
versus comparator EGFR TKI as First-line treatment for EGFR-mutated
advanced NSCLC: FLAURA China, A randomized study. Target Oncol.
16:165–176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu L, Zhong W, Li A, Qiu Z, Xie R, Shi H
and Lu S: Successful treatment of EGFR T790M-mutant non-small cell
lung cancer with almonertinib after osimertinib-induced
interstitial lung disease: A case report and literature review. Ann
Transl Med. 9:9502021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leighl NB, Karaseva N, Nakagawa K, Cho BC,
Gray JE, Hovey T, Walding A, Rydén A and Novello S:
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib
or gefitinib in patients with EGFR-mutated advanced non-small-cell
lung cancer. Eur J Cancer. 125:49–57. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Reungwetwattana T, Nakagawa K, Cho BC,
Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, et
al: CNS response to osimertinib versus standard epidermal growth
factor receptor tyrosine kinase inhibitors in patients with
untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin
Oncol: Jco2018783118. 2018.doi: 10.1200/JCO.2018.78.3118 (Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu S, Wang Q, Zhang G, Dong X, Yang CT,
Song Y, Chang GC, Lu Y, Pan H, Chiu CH, et al: Efficacy of
aumolertinib (HS-10296) in patients with advanced EGFR T790M+
NSCLC: updated post-national medical products administration
approval results from the APOLLO registrational trial. J Thorac
Oncol. 17:411–422. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shirley M and Keam SJ: Aumolertinib: A
review in non-small cell lung cancer. Drugs. 82:577–584. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lu S, Dong X, Jian H, Chen J, Chen G, Sun
Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III
trial of aumolertinib versus gefitinib as First-line therapy for
locally advanced or metastaticnon-small-cell lung cancer with EGFR
exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Benjamin DJ and Nagasaka M: Freeing the
competition: Will aumolertinib (AENEAS) have a fighting chance
against osimertinib (FLAURA)? J Clin Oncol. 41:742–744. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shi Y, Hu X, Zhang S, Lv D, Wu L, Yu Q,
Zhang Y, Liu L, Wang X, Cheng Y, et al: Efficacy, safety, and
genetic analysis of furmonertinib (AST2818) in patients with EGFR
T790M mutated non-small-cell lung cancer: A phase 2b, multicentre,
single-arm, open-label study. Lancet Respir Med. 9:829–839. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y,
Liu C, Zhu S, Zhang X, Li Y, et al: Furmonertinib (AST2818) versus
gefitinib as first-line therapy for Chinese patients with locally
advanced or metastatic EGFR mutation-positive non-small-cell lung
cancer (FURLONG): A multicentre, double-blind, randomised phase 3
study. Lancet Respir Med. 10:1019–1028. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y,
Liu C, Zhu S, Zhang X, Li Y, et al: Central Nervous system efficacy
of furmonertinib (AST2818) versus gefitinib as first-line treatment
for EGFR-mutated NSCLC: Results from the FURLONG study. J Thorac
Oncol. 17:1297–1305. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Park K, Jӓnne PA, Kim DW, Han JY, Wu MF,
Lee JS, Kang JH, Lee DH, Cho BC, Yu CJ, et al: Olmutinib in
T790M-positive non-small cell lung cancer after failure of
first-line epidermal growth factor receptor-tyrosine kinase
inhibitor therapy: A global, phase 2 study. Cancer. 127:1407–1416.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Murtuza A, Bulbul A, Shen JP, Keshavarzian
P, Woodward BD, Lopez-Diaz FJ, Lippman SM and Husain H: Novel
Third-generation EGFR tyrosine kinase inhibitors and strategies to
overcome therapeutic resistance in lung cancer. Cancer Res.
79:689–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee J, Hong MH and Cho BC: Lazertinib: On
the Way to Its Throne. Yonsei Med J. 63:799–805. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cho BC, Han JY, Kim SW, Lee KH, Cho EK,
Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, et al: A Phase 1/2 Study of
Lazertinib 240 mg in patients with advanced EGFR T790M-positive
NSCLC after previous EGFR tyrosine kinase inhibitors. J Thorac
Oncol. 17:558–567. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cho BC, Ahn MJ, Kang JH, Soo RA,
Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, et al:
Lazertinib versus gefitinib as First-line treatment in patients
with EGFR-mutated advanced non-small-cell lung cancer: Results from
LASER301. J Clin Oncol. 41:4208–4217. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cho BC, Kim DW, Spira AI, Gomez JE, Haura
EB, Kim SW, Sanborn RE, Cho EK, Lee KH, Minchom A, et al:
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant
advanced non-small cell lung cancer: A phase 1 trial. Nat Med.
14:023–02554. 2023.
|
|
61
|
Tan DSW, Kim SW, Ponce Aix S, Sequist LV,
Smit EF, Yang JCH, Hida T, Toyozawa R, Felip E, Wolf J, et al:
Nazartinib for treatment-naive EGFR-mutant non-small cell lung
cancer: Results of a phase 2, single-arm, open-label study. Eur J
Cancer. 172:276–286. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhou Q, Wu L, Hu P, An T, Zhou J, Zhang L,
Liu XQ, Luo F, Zheng X, Cheng Y, et al: A Novel Third-generation
EGFR Tyrosine kinase inhibitor abivertinib for EGFR T790M-mutant
Non-small cell lung cancer: A multicenter phase I/II study. Clin
Cancer Res. 28:1127–1135. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang F and Zhou Q: The challenges of
Third-generation EGFR tyrosine kinase inhibitors in the therapy of
advanced NSCLC. J Thorac Oncol. 17:481–486. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Azuma K, Nishio M, Hayashi H, Kiura K,
Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, et
al: ASP8273 tolerability and antitumor activity in tyrosine kinase
inhibitor-naïve Japanese patients with EGFR mutation-positive
non-small-cell lung cancer. Cancer Sci. 109:2532–2538. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cho BC, Goldberg SB, Kim DW, Socinski MA,
Burns TF, Lwin Z, Pathan N, Ma WD, Masters JC, Cossons N, et al: A
phase 1b/2 study of PF-06747775 as monotherapy or in combination
with Palbociclib in patients with epidermal growth factor receptor
mutant advanced non-small cell lung cancer. Expert Opin Investig
Drugs. 31:747–757. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shi Y, Li B, Wu L, Pan Y, Pan Z, Liu Y,
Fan Y, Ji Y, Fang J, Shi Q, et al: Efficacy and safety of
limertinib (ASK120067) in patients with locally advanced or
metastatic EGFR Thr790Met-mutated NSCLC: A multicenter, single-arm,
phase 2b study. J Thorac Oncol. 17:1205–1215. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang T, Qu R, Chan S, Lai M, Tong L, Feng
F, Chen H, Song T, Song P, Bai G, et al: Discovery of a novel
third-generation EGFR inhibitor and identification of a potential
combination strategy to overcome resistance. Mol Cancer. 19:902020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lu S, Zhang Y, Zhang G, Zhou J, Cang S,
Cheng Y, Wu G, Cao P, Lv D, Jian H, et al: Efficacy and safety of
befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC
that had progressed after prior EGFR tyrosine kinase inhibitor
therapy: A phase 2, multicenter, single-arm, open-label study. J
Thorac Oncol. 17:1192–1204. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Han L, Zhang X, Wang Z, Zhang X, Zhao L,
Fu W, Liang X, Zhang Z and Wang Y: SH-1028, An irreversible
Third-generation EGFR TKI, overcomes T790M-mediated resistance in
non-small cell lung cancer. Front Pharmacol. 12:6652532021.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xiong A, Ren S, Liu H, Miao L, Wang L,
Chen J, Li W, Li R, Wang X, Lu Z, et al: Efficacy and Safety of
SH-1028 in patients with EGFR T790M-positive NSCLC: A multicenter,
single-arm, open-label, phase 2 trial. J Thorac Oncol.
17:1216–1226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ito K, Nishio M, Kato M, Murakami H,
Aoyagi Y, Ohe Y, Okayama T, Hashimoto A, Ohsawa H, Tanaka G, et al:
TAS-121, A selective mutant EGFR inhibitor, shows activity against
tumors expressing various EGFR mutations including T790M and
uncommon mutations G719X. Mol Cancer Ther. 18:920–928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A
randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer
M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus
gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C
and Wang Z: Anlotinib combined with osimertinib reverses acquired
osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL
axis. Pharmacol Res. 188:1066682023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jia Y, Yun CH, Park E, Ercan D, Manuia M,
Juarez J, Xu C, Rhee K, Chen T, Zhang H, et al: Overcoming
EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature. 534:129–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im
K, Lee H, Lee CW, Cho J, Min J, Woo DC, et al: The reversible
fourth-generation EGFR tyrosine kinase inhibitor OBX02-011
overcomes C797S-mediated resistance in lung cancer. Cancer Res. Jun
14–2022.(Epub ahead of print). doi: 10.1158/0008-5472.CAN-22-0394.
View Article : Google Scholar
|
|
77
|
Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang
T, Tong L, Zhang M, Chen H, Chen Y, et al: LS-106, a novel EGFR
inhibitor targeting C797S, exhibits antitumor activities both in
vitro and in vivo. Cancer Sci. 113:709–720. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kashima K, Kawauchi H, Tanimura H,
Tachibana Y, Chiba T, Torizawa T and Sakamoto H: CH7233163
overcomes osimertinib-resistant EGFR-Del19/T790M/C797S mutation.
Mol Cancer Ther. 19:2288–2297. 2020. View Article : Google Scholar : PubMed/NCBI
|
